Tufts University

Bach Biosciences, LLC

New England Medical Center Hospitals. Inc.

1149336 Ontario, Inc.

Arisaph Pharmaceuticals, Inc.

E.i. Dupont De Nemours and Company

The Brigham and Women's Hospital, Inc.

William W Bachovchin

Hung-sen Lai

Wengen Wu

Sarah E Poplawski

David George Sanford

Andrew G Plaut

Daniel J Drucker

Christopher P Kiritsy

Daniel Philip O'Connell

George R Flentke

Vijay K Kuchroo

Charles A Kettner

Flentke George R

Hung-Sen Lai

Daniel O'CONNELL

Disclosed are combination therapies including administration of I-DASH inhibitors and PGE2 antagonists, and the use of such therapies in the treatment of cell proliferative diseases.

Combination therapies using immuno-DASH inhibitors and PGE2 antagonists

Disclosed are proteasome inhibitors, fibroblast activation protein (FAP)-activated prodrugs of proteasome inhibitors, and pharmaceutically acceptable salts of the inhibitors and prodrugs. Also disclosed are related pharmaceutical compositions, and methods of using the inhibitors and prodrugs and compositions thereof, for example, in treating cancer or other cell proliferative diseases. In vitro and in vivo methods of quantifying the expression of FAP in a biopsy sample and a mammal, respectively, are also disclosed.

FAP-activated proteasome inhibitors for treating solid tumors

Disclosed are prodrugs of cytotoxic anthracyclines (such as doxorubicin) and other therapeutic agents that are selectively cleaved and activated by fibroblast activating protein (FAP). The prodrugs are useful for targeted delivery of cytotoxic and other agents to FAP-expressing tissues, including cancer (e.g., solid tumors). Also provided are pharmaceutical compounds comprising the prodrugs, as well as methods of using the prodrugs to treat a disorder characterized by FAP upregulation, e.g., cancer, fibrosis, and inflammation.

Fap-activated therapeutic agents, and uses related thereto

FAP-activated therapeutic agents, and uses related thereto

Combination therapies using immuno-dash inhibitors and PGE2 antagonists

Disclosed are prodrugs of anthracyclines (such as doxorubicin) and derivatives thereof that are selectively cleaved and activated by fibroblast activating protein (FAP). The prodrugs are useful for targeted delivery of 'warhead' anthracycline or anthracycline derivative to FAP-expressing tissues, including cancer (e.g., solid tumors). Also provided are pharmaceutical compounds comprising the prodrugs, as well as methods of using the prodrugs to treat a disorder characterized by FAP upregulation, e.g., cancer undesirable fibrosis and undesirable inflammation.

The tumor stroma, which accounts for a large part of the tumor mass, represents an attractive target for the delivery of diagnostic and therapeutic compounds. Here, the focus is notably on a subpopulation of stromal cells, known as cancer-associated fibroblasts, which are present in more than 90% of epithelial carcinomas, including pancreatic, colon, and breast cancer. Cancer-associated fibroblasts feature high expression of FAP, which is not detectable in adult normal tissue but is associated with a poor prognosis in cancer patients. The present invention provides small-molecule radiopharmaceutical and imaging agents based on a FAP-specific inhibitor.

FAP-targeted radiopharmaceuticals and imaging agents, and uses related thereto

Disclosed are potent immuno-DASH inhibitors and their use in the treatment of cell proliferative diseases.

Dash inhibitors, and uses related thereto

Disclosed are combination therapies including administration of Caspase-1 dependent anticancer agents and PGE2 antagonists, and the use of such therapies in the treatment of cell proliferative diseases.

Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists

Disclosed are prodrugs of anthracyclines (such as doxorubicin) and derivatives thereof that are selectively cleaved and activated by fibroblast activating protein (FAP). The prodrugs are useful for targeted delivery of 'warhead' anthracycline or anthracycline derivative to FAP-expressing tissues, including cancer (e.g., solid tumors). Also provided are pharmaceutical compounds comprising the prodrugs, as well as methods of using the prodrugs to treat a disorder characterized by FAP upregulation, e.g., cancer, undesirable fibrosis, and undesirable inflammation.

Growing community of inventors

Cambridge, MA, United States of America

William W Bachovchin